IE
ANTX icon

Israel Englander’s AN2 Therapeutics ANTX Stock Holding History

Israel Englander’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.2M Buy
2,318,692
+96,190
+4% +$414K ﹤0.01% 2174
2026
Q1 		$7.6M Buy
2,222,502
+2,126,819
+2,223% +$4.39M ﹤0.01% 2462
2025
Q4 		$109K Buy
+95,683
New +$112K ﹤0.01% 5619
2025
Q2 		– Sell
-50,038
Closed -$68.1K – 5831
2025
Q1 		$68.1K Sell
50,038
-159,328
-76% -$201K ﹤0.01% 5495
2024
Q4 		$289K Sell
209,366
-188,559
-47% -$229K ﹤0.01% 5095
2024
Q3 		$426K Sell
397,925
-128,427
-24% -$223K ﹤0.01% 4953
2024
Q2 		$1.13M Buy
526,352
+429,438
+443% +$1.02M ﹤0.01% 4015
2024
Q1 		$315K Buy
96,914
+57,240
+144% +$623K ﹤0.01% 5106
2023
Q4 		$813K Buy
+39,674
New +$664K ﹤0.01% 4313
2023
Q3 		– Sell
-24,242
Closed -$206K – 6084
2023
Q2 		$206K Buy
+24,242
New +$174K ﹤0.01% 5100
2022
Q2 		– Sell
-74,238
Closed -$1.12M – 6931
2022
Q1 		$1.12M Buy
+74,238
New +$1.13M ﹤0.01% 4421

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Israel Englander's ANTX Position: Q2 2026 in Review

Israel Englander increased its AN2 Therapeutics (ANTX) stake by 4.3% in Q2 2026, buying an estimated $414K and bringing the position to 2,318,692 shares worth $11.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2174.

Israel Englander first reported a position in ANTX in Q1 2022 and has held it in 11 quarters since. 66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • Israel Englander held 2,318,692 shares of AN2 Therapeutics worth $11.2M as of Q2 2026.
  • Israel Englander bought 96,190 AN2 Therapeutics shares in Q2 2026, an estimated $414K.
  • AN2 Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2174 holding.
  • Israel Englander first reported a position in AN2 Therapeutics in Q1 2022 and has held it in 11 quarters since.
  • 66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.